Chemical Name:[[3,4-Dihydro-7-(4-morpholinyl)-2,3-dioxo-6-(trifluorom
ethyl)-1(2H)-quinoxalinyl]methyl]phosphonic acid
Biological Activity:
Competitive
AMPA/kainate antagonist. In rat cortical membranes, displays high affinity for
[3H]-AMPA (Ki = 120 nM) and [3H]-CNQX (Ki
= 32 nM) binding sites and low affinity for kainate and NMDA channel-associated
binding sites (IC50 values range from 2.5 to 11 μM). Inhibits currents induced by
AMPA, kainate and NMDA with IC50 values of 21 nM, 27 nM, and > 1 μM respectively. Displays anxiolytic,
anticonvulsant and muscle relaxant activity in vivo.
Turskiet
al (1998) ZK200775: a phosphonate quinoxalinedione AMPA antagonist for
neuroprotection in stroke and trauma. Proc.Natl.Acad.Sci.USA. 95
10960. Kosowskiet al (2004) Nicotine-induced dopamine release in
the nucleus accumbens is inhibited by the novel AMPA antagonist ZK200775 and
the NMDA antagonist CGP39551. Pychopharmacology 175 114.Elger et al
(2005) Novel α-amino-3-hydroxy-5-methyl-4-isoxazole
propionate (AMPA) receptor antagonists of 2,3-benzodiazepine type: chemical
synthesis, in vitro characterization, and in vivo prevention of acute
neurodegeneration. J.Med.Chem. 48 4618.
Displays 26-fold and > 440-fold selectivity over kainate and NMDA receptors respectively. Neuro-protective; delays neuronal death in a global ischaemia model and cerebral infarction in a focal ischaemia model.